bullish

Cybin

Cybin, Inc. - CYB003 Demonstrates Exceptional Durable Treatment Benefits for Depression

118 Views20 Nov 2024 09:31
Issuer-paid
CYB003 also demonstrated an excellent safety profile, with no new adverse events reported in the 12- month follow-up, including no reports of suicidality.
What is covered in the Full Insight:
  • Introduction to CYB003 Data
  • Phase 2 Efficacy Results
  • Phase 3 Program Details
  • Upcoming Catalysts
  • Market and Valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 7-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x